PGGM Investments Buys New Shares in Grail, Inc. (NASDAQ:GRAL)

PGGM Investments purchased a new position in Grail, Inc. (NASDAQ:GRAL) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 68,560 shares of the company’s stock, valued at approximately $1,224,000. PGGM Investments owned about 0.20% of Grail at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. FNY Investment Advisers LLC purchased a new stake in Grail during the fourth quarter valued at about $26,000. Lindbrook Capital LLC acquired a new stake in Grail in the 4th quarter valued at $28,000. New York State Common Retirement Fund purchased a new position in Grail in the fourth quarter valued at about $59,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Grail during the fourth quarter worth about $64,000. Finally, PNC Financial Services Group Inc. acquired a new position in shares of Grail during the fourth quarter worth about $86,000.

Insiders Place Their Bets

In other news, CEO Robert P. Ragusa sold 7,625 shares of the firm’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $31.21, for a total transaction of $237,976.25. Following the transaction, the chief executive officer now directly owns 828,662 shares of the company’s stock, valued at approximately $25,862,541.02. This trade represents a 0.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Aaron Freidin sold 1,816 shares of the firm’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $31.20, for a total transaction of $56,659.20. Following the transaction, the chief financial officer now directly owns 335,170 shares in the company, valued at approximately $10,457,304. The trade was a 0.54 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,550 shares of company stock worth $360,436.

Analyst Ratings Changes

GRAL has been the subject of a number of recent analyst reports. Wolfe Research began coverage on shares of Grail in a report on Friday, November 15th. They set a “peer perform” rating for the company. Morgan Stanley initiated coverage on Grail in a research note on Wednesday, November 27th. They set an “equal weight” rating and a $16.00 target price for the company.

Grail Stock Down 12.7 %

NASDAQ:GRAL opened at $26.92 on Friday. The business’s 50 day moving average is $31.60 and its two-hundred day moving average is $21.19. Grail, Inc. has a 52 week low of $12.33 and a 52 week high of $63.99.

Grail (NASDAQ:GRAL) last released its quarterly earnings data on Thursday, February 20th. The company reported ($1.86) earnings per share for the quarter, topping the consensus estimate of ($4.41) by $2.55. The business had revenue of $38.25 million for the quarter, compared to analyst estimates of $35.33 million. As a group, equities analysts expect that Grail, Inc. will post -15.15 EPS for the current year.

About Grail

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.